The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Long-Term Use of Antidepressants for Depressive Disorders and the Risk of Diabetes Mellitus
Abstract
OBJECTIVE: Use of antidepressants has been reported to cause considerable weight gain. The aim of this study was to assess the risk of diabetes mellitus associated with antidepressant treatment and to examine whether the risk is influenced by treatment duration or daily dose. METHOD: This was a nested case-control study in a cohort of 165,958 patients with depression who received at least one new prescription for an antidepressant between January 1, 1990, and June 30, 2005. Data were from from the U.K. General Practice Research Database. Patients were at least 30 years of age and without diabetes at cohort entry. RESULTS: A total of 2,243 cases of incident diabetes mellitus and 8,963 matched comparison subjects were identified. Compared with no use of antidepressants during the past 2 years, recent long-term use (>24 months) of antidepressants in moderate to high daily doses was associated with an increased risk of diabetes (incidence rate ratio=1.84, 95% CI=1.35-2.52). The magnitude of the risk was similar for long-term use of moderate to high daily doses of tricyclic antidepressants (incidence rate ratio=1.77, 95% CI=1.21-2.59) and selective serotonin reuptake inhibitors (incidence rate ratio=2.06, 95% CI=1.20-3.52). Treatment for shorter periods or with lower daily doses was not associated with an increased risk. CONCLUSIONS: Long-term use of antidepressants in at least moderate daily doses was associated with an increased risk of diabetes. This association was observed for both tricyclic antidepressants and selective serotonin reuptake inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Jick, H., Jick, S. S., & Derby, L. E. (1991) · BMJ · doi:10.1136/bmj.302.6779.766 · Cited by 839
The UK General Practice Research Database
Walley, T., & Mantgani, A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04248-7 · Cited by 623
Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia
Sernyak, M. J., Leslie, D. L., Alarcon, R. D., Losonczy, M. F., & Rosenheck, R. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.4.561 · Cited by 623
Validity of the General Practice Research Database
Jick, S. S., Kaye, J. A., Vasilakis‐Scaramozza, C., Rodríguez, L. A. G., Ruigómez, A., Meier, C. R., Schlienger, R. G., Black, C., & Jick, H. (2003) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.5.686.32205 · Cited by 584
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R. (2002) · BMJ · doi:10.1136/bmj.325.7358.243 · Cited by 421
Zimmermann, U., Kraus, T., Himmerich, H., Schuld, A., & Pollmächer, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00018-9 · Cited by 347
Fava, M., Judge, R., Hoog, S. L., Nilsson, M. E., & Koke, S. C. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1109 · Cited by 263
Silverstone, P. H., Ravindran, A., & the Venlafaxine XR 360 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0105 · Cited by 246
Rubin, R. R., Ma, Y., Marrero, D. G., Peyrot, M., Barrett-Connor, E. L., Kahn, S. E., Haffner, S. M., Price, D. W., Knowler, W. C., & for the Diabetes Prevention Program Research Group (2008) · Diabetes Care · doi:10.2337/dc07-1827 · Cited by 242
Amitriptyline, Weight Gain and Carbohydrate Craving: A Side Effect
Paykel, E. S., Mueller, P. S., & De la Vergne, P. M. (1973) · British Journal of Psychiatry · doi:10.1192/bjp.123.5.501 · Cited by 215
Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
Hermansen, K., & Mortensen, L. S. (2007) · Drug Safety · doi:10.2165/00002018-200730120-00005 · Cited by 174
Raeder, M. B., Bjelland, I., Vollset, S. E., & Steen, V. M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1219 · Cited by 171
Sussman, N., Ginsberg, D. L., & Bikoff, J. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0407 · Cited by 169
Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder
Liebowitz, M. R., Gelenberg, A. J., & Munjack, D. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.190 · Cited by 160
Sussman, N., Ginsberg, D. L., & Bikoff, J. (2001) · PubMed · Cited by 138
Rudolph, R. L., Fabre, L. F., Feighner, J. P., Rickels, K., Entsuah, R., & Derivan, A. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0305 · Cited by 132
Glucose Intolerance with Atypical Antipsychotics
Hedenmalm, K., gg, S. H., hl, M. S., Mortimer, ?., & Spigset, O. (2002) · Drug Safety · doi:10.2165/00002018-200225150-00005 · Cited by 124
Weight Gain with Antidepressants and Lithium
Garland, E., Remick, R. A., & Zis, A. P. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198810000-00003 · Cited by 119
Derijks, H. J., Meyboom, R. H. B., Heerdink, E. R., Koning, F. H. P. D., Janknegt, R., Lindquist, M., & Egberts, T. C. G. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0441-y · Cited by 110
Kornegay, C. J., Vasilakis‐Scaramozza, C., & Jick, H. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0902 · Cited by 98
Neuropharmacology of Paradoxic Weight Gain with Selective Serotonin Reuptake Inhibitors
Harvey, B. H., & Bouwer, C. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200003000-00006 · Cited by 97
Åberg‐Wistedt, A., Ågren, H., Ekselius, L., Bengtson, F., & Åkerblad, A. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00010 · Cited by 95
Type of antidepressant therapy and risk of type 2 diabetes in people with depression
Brown, L. C., Majumdar, S. R., & Johnson, J. A. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.07.009 · Cited by 92
Antidepressant-induced weight gain: A comparison study of four medications
Fernstrom, M. H., & Kupfer, D. J. (1988) · Psychiatry Research · doi:10.1016/0165-1781(88)90120-5 · Cited by 77
Lambert, B. L., Chou, C., Chang, K., Tafesse, E., & Carson, W. H. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1092 · Cited by 76
Safety and tolerance profile of venlafaxine
Danjou, P., & Hackett, D. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199503002-00004 · Cited by 72
Kazès, M., Danion, J., Grangé, D., Pradignac, A., Simon, C., Burrus-Mehl, F., Schlienger, J.-L., & Singer, L. (1994) · Journal of Affective Disorders · doi:10.1016/0165-0327(94)90080-9 · Cited by 66
Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases
Levkovitz, Y., Ben-shushan, G., Herschkovitz, A., Isaac, R., Gil‐Ad, I., Shvartsman, D. E., Ronen, D., Weizman, A., & Zick, Y. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.05.009 · Cited by 65
Yamada, J., Sugimoto, Y., & Inoue, K. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00593-2 · Cited by 63
No increased incidence of diabetes in antidepressant users
Knol, M. J., Geerlings, M. I., Egberts, T. C. G., Gorter, K. J., Grobbee, D. E., & Heerdink, E. R. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282202c0e · Cited by 59
Changes in Weight During Treatment for Depression
Kupfer, D. J., Coble, P. A., & Rubinstein, D. (1979) · Psychosomatic Medicine · doi:10.1097/00006842-197911000-00004 · Cited by 43
Tolerability of High-Dose Venlafaxine in Depressed Patients
Harrison, C., Ferrier, N., & Young, A. H. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042621 · Cited by 41
Carvalho, F., Barros, D., Silva, J., REZENDE, E. M. D., Soares, M. F. D. P., Fregoneze, J. B., & Silva, E. D. C. E. (2004) · Neuropeptides · doi:10.1016/j.npep.2004.04.004 · Cited by 32
Glucose Dysregulation and Mirtazapine-Induced Weight Gain
Fisfalen, M. E., & Hsiung, R. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.797 · Cited by 32
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Depression in type 2 diabetes mellitus: prevalence, impact, and treatment
Semenkovich, K., Brown, M. E., Svrakic, D. M., & Lustman, P. J. (2015) · Drugs · doi:10.1007/s40265-015-0347-4 · Cited by 447
Efficacy and effectiveness of antidepressants: current status of research
Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000318293 · Cited by 347
Metadata
- Authors
- Andersohn, F., Schade, R., Suissa, S., & Garbe, E.
- Venue
- American Journal of Psychiatry
- Published
- 2009-05
- Volume
- 166
- Issue
- 5
- Pages
- 591-598
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2171799186
- Cited by
- 314
- References
- 36
- FWCI
- 21.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.